Lucite tombstone marking the acquisition of Catalyst Regulatory Services, which provides regulatory support for biopharmaceutical firms.
(20AMF027)
Whether you’re celebrating a funding round, research collaboration, FDA-approval, or commemorating a deal in the biotech space, you’ll find inspiration in the custom designs below.
Lucite tombstone marking the acquisition of Catalyst Regulatory Services, which provides regulatory support for biopharmaceutical firms.
(20AMF027)Lucite tombstone commemorating a follow-on offering by medTech firm Viveve Medical, which specializes in women’s health.
(20AMF021)Custom financial tombstone recognizing a follow-on offering by Turning Point Therapeutics. Turning Point is a clinical-stage biopharmaceutical company focused on oncology therapies.
(9ALJ524)Lucite tombstone commemorating a public offering of stock by Achieve Life Sciences. Achieve is engaged in the development and cytisinicline, a plant-based alkaloid used for smoking cessation and nicotine addiction.
(20AMF022)Custom Lucite tombstone commemorating the acquisition of Quadrants Scientific, a San Diego-based chemical and microbiological testing laboratory.
(20ALJ029)Lucite deal toy commemorating several U.S. private placements by Australia-based Sonic Healtcare.
(9AJH188)Crystal deal toy marking a private placement by Colorado-based pharmaceutical firm Aytu Bioscience.
(9AMF327)Custom Lucite commemorating the acquisition of Igenomix, a Spanish provider of genetic testing services for reproductive health patients.
(9LSS177)Beginning on this page, you’ll find galleries with over 90 images of financial tombstones and deal toys from the biotech and life sciences space. You’ll find a number of custom designs playing off visual elements commonly associated with this space, including DNA strands, pills, lab beakers, periodic tables, as well as ones incorporating actual drug vials.
As you might also expect, you’ll see a number of deal toys involving internationally recognized firms and players. These include Takeda Pharmaceutical, Horizon Therapeutics, Gilead Sciences, Roche, Neurocrine, and Bayer. You’ll see as well tombstones commemorating transactions common to this sector involving these and other firms: joint ventures, licensing deals, and development and commercialization agreements.
But you’ll also notice a number of deals commemorated here that may involve far less familiar firms. These include the acquisition of a Dutch company focused on live-cell imaging analytics, and one of an Illinois-based gene therapy firm devoted to the treatment of a rare genetic disorder; the initial public offering of an Australian developer of radiopharmaceutical cancer therapies, and the IPO of a Norwegian biotech making use of marine compounds such as herring roe extract; early-stage funding for a Philadelphia gene engineering startup, and the IPO of an Israeli firm focused on medical applications for lipid-based compounds.
You’ll also notice in these galleries designs not related to any financial transaction. These celebrate a range of awards and employee recognition pieces honoring successful clinical trials, Food and Drug Administration (FDA) and New Drug Application (NDA) submissions, research collaborations and partnerships, and product development milestones.
"*" indicates required fields
